All In Biotech

Drug Trial Radar · NCT03754790

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

281

Actual

Start

Jan 9, 2019

Primary completion

Sep 14, 2026

Study completion Sep 14, 2026

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Nov 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: * To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of: * Bleeding episodes * Spontaneous bleeding episodes * Joint bleeding episodes * To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age

Conditions

  • Hemophilia

Interventions

  • FitusiranDrug

    Pharmaceutical form:solution for injection Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events (TEAEs)Time frame: from study baseline (day 1) up to maximum 88 months

Locations

79 sites in 20 countries. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital Site Number : 8400009

    Phoenix, Arizona

  • Children's Hospital Los Angeles Site Number : 8400019

    Los Angeles, California

  • Center for Inherited Blood Disorders (CIBD) Site Number : 8400016

    Orange, California

  • Nemours Children's Clinic Site Number : 8400008

    Jacksonville, Florida

  • St Joseph's Children's Hospital of Tampa Site Number : 8400002

    Tampa, Florida

  • Rush University Medical Center -1725 W Harrison St Site Number : 8400001

    Chicago, Illinois

  • ~Massachusetts General Hospital Site Number : 8400011

    Boston, Massachusetts

  • University of Michigan Hospital - 1500 E Medical Center Dr Site Number : 8400012

    Ann Arbor, Michigan

  • Alliance for Childhood Diseases Site Number : 8400007

    Las Vegas, Nevada

  • Childrens Hospital Medical Center of Akron Site Number : 8400006

    Akron, Ohio

  • Investigational Site Number : 0360001

    Camperdown, New South Wales, Australia

  • Investigational Site Number : 0360003

    Prahran, Victoria, Australia

  • Investigational Site Number : 0360002

    Murdoch, Western Australia, Australia

  • Investigational Site Number : 1240001

    Montreal, Quebec, Canada

  • Investigational Site Number : 1560004

    Beijing, China

  • Investigational Site Number : 1560007

    Beijing, China

  • Investigational Site Number : 1560014

    Changsha, China

  • Investigational Site Number : 1560009

    Chengdu, China

  • Investigational Site Number : 1560002

    Guangzhou, China

  • Investigational Site Number : 1560011

    Guiyang, China

  • Investigational Site Number : 1560005

    Hangzhou, China

  • Investigational Site Number : 1560008

    Jinan, China

  • Investigational Site Number : 1560012

    Kunming, China

  • Investigational Site Number : 1560013

    Lanzhou, China

  • Investigational Site Number : 1560010

    Qingdao, China

  • Investigational Site Number : 1560003

    Shanghai, China

  • Investigational Site Number : 1560006

    Suzhou, China

  • Investigational Site Number : 2080001

    Copenhagen, Denmark

  • Investigational Site Number : 2500002

    Lyon, France

  • Investigational Site Number : 2500003

    Paris, France

  • Investigational Site Number : 2760001

    Berlin, Germany

  • Investigational Site Number : 2760003

    Leipzig, Germany

  • Investigational Site Number : 3480002

    Budapest, Hungary

  • Investigational Site Number : 3560001

    Bangalore, India

  • Investigational Site Number : 3560005

    Lucknow, India

  • Investigational Site Number : 3560007

    Mumbai, India

  • Investigational Site Number : 3560002

    Pune, India

  • Investigational Site Number : 3560010

    Pune, India

  • Investigational Site Number : 3560004

    Ranipet, India

  • Investigational Site Number : 3720002

    Dublin, Ireland

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.